Please use this identifier to cite or link to this item:
|Title:||Recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein - A preliminary study on immunogenicity|
|Authors:||Yap, I. |
|Citation:||Yap, I., Guan, R., Chan, S.H. (1992). Recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein - A preliminary study on immunogenicity. Vaccine 10 (7) : 439-442. ScholarBank@NUS Repository.|
|Abstract:||A novel recombinant hepatitis B vaccine, trademarked Sci-B-Vac, was evaluated for safety, tolerability and immunogenicity in an open label trial performed in Singapore. The experimental vaccine, derived from Chinese hamster ovary (CHO) cells, consists of hepatitis B surface antigen (HBsAg) particles harbouring all three viral envelope polypeptides, the major S protein and the minor Pre-S2 and Pre-S1, in their glycosylated and non-glycosylated forms. The vaccine was administered intramuscularly at 0, 1 and 6 months. No unexpected adverse effects were observed. A high level anti-HBs response to Sci-B-Vac was indicative of its immunogenicity. Subsequent to the third injection, 100% and 92% of the 10 μg and 5 μg dose recipients, respectively, were seroprotected (anti-HBs titres ≥ 10 mIU ml -1). Moreover, the geometric mean titres (GMT) of the anti-HBs response were very high: 2687 and 1473 mIU ml -1, respectively. An immunogenic advantage of Sci-B-Vac was also suggested by the rapid onset of antibody response: 96% of the 10 μg dose recipients were seroprotected with a GMT of 159 mIU ml -1, prior to the third injection.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 14, 2018
WEB OF SCIENCETM
checked on May 8, 2018
checked on Apr 19, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.